INmune Bio's CORDStrom Platform Featured in Peer-Reviewed Study on Mesenchymal Stromal Cell Therapies
核心洞察
A peer-reviewed study in Cytotherapy journal highlights the therapeutic potential of mesenchymal stromal cell therapies, featuring INmune Bio's CORDStrom (搜索) platform as a key example.
INmune Bio's lead scientist Dr. Nikita M. Patel served as one of the lead authors for the invitation-only working party publication examining MSC therapy development.
The company expects to file BLA and MAA applications for CORDStrom (搜索) in recessive dystrophic epidermolysis bullosa (搜索) by 2026.
INmune Bio, Inc. (NASDAQ: INMB) announced that its CORDStrom (搜索) platform has been featured in a comprehensive peer-reviewed study examining the future of mesenchymal stromal cell (MSC) therapies. The article, titled "Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions," was published in the journal Cytotherapy and represents a significant scientific milestone for the clinical-stage inflammation and immunology company.
Scientific Collaboration and Publication Details
The publication emerged from an invitation-only working party comprising basic, clinical, and translational scientists specializing in MSC research. Dr. Nikita M. Patel, INmune Bio's lead scientist for CORDStrom (搜索) R&D, served as one of the lead authors of the paper. The study reviews the current knowledge base and identifies critical gaps in MSC therapy development, formulating experimental questions designed to enhance the development of MSC therapies such as the CORDStrom platform.
The research examined key aspects of MSC therapy delivery, including systemic delivery methods, local and depot-delivery approaches, and in vivo persistence. Notably, the CORDStrom (搜索) platform utilizes local and depot-delivery methods, positioning it within the current scientific discourse on optimal MSC administration strategies.
CORDStrom Platform Technology
CORDStrom (搜索) (pobistrocel (搜索)) represents a patent-pending cell medicine comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. The platform leverages proprietary screening, pooling, and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs designed to treat complex inflammatory, degenerative, and autoimmune diseases.
The technology is engineered to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured cellular medicines that can be produced affordably with repeatable specifications, independent of donor characteristics. While the first-generation CORDStrom (搜索) product is agnostic to disease indication, the platform enables creation of indication-specific products that can be optimized for anti-inflammatory, immunomodulatory, wound healing, and other therapeutic characteristics.
Regulatory Timeline and Clinical Development
INmune Bio is initially developing CORDStrom (搜索) for recessive dystrophic epidermolysis bullosa (搜索) (RDEB), with plans to file a Biologics License Application (BLA) and Marketing Authorization Application (MAA) in 2026. The platform recently completed a randomized, double-blinded study in RDEB patients, marking a significant milestone in its clinical development trajectory.
Dr. Mark Lowdell, INmune Bio's Chief Scientific Officer, emphasized the broader implications of the research: "Stromal cell therapies are an important clinical advancement that may have significant impact in multiple indications including inflammation, immunomodulation, and wound healing. Nikita's role within INmuneBio supports continued advancement in the knowledge base on MSCs."
Scientific Impact and Future Directions
The publication provides important scientific background for future development of the CORDStrom (搜索) platform beyond its initial RDEB indication. Dr. Lowdell noted that the contributions made by Dr. Patel as one of the senior authors, along with the insightful questions posed by the scientific panel, are expected to have significant impact on MSC development in general, in addition to supporting the ongoing advancement of the CORDStrom platform.
The research addresses fundamental questions about MSC therapy optimization, delivery methods, and therapeutic persistence that are crucial for advancing the entire field of regenerative medicine. As the scientific community continues to explore the therapeutic potential of MSC-based treatments, publications like this provide essential frameworks for future clinical development and regulatory strategies.